Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern
The global coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spawned an ongoing demand for new research reagents and interventions. Herein we describe a panel of monoclonal antibodies raised against SARS-CoV-2. One antibody sh...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/15/1/139 |
| _version_ | 1827621345929723904 |
|---|---|
| author | Mahali S. Morgan Kexin Yan Thuy T. Le Ryan A. Johnston Alberto A. Amarilla David A. Muller Christopher L. D. McMillan Naphak Modhiran Daniel Watterson James R. Potter Julian D.J. Sng Mary Lor Devina Paramitha Ariel Isaacs Alexander A. Khromykh Roy A. Hall Andreas Suhrbier Daniel J. Rawle Jody Hobson-Peters |
| author_facet | Mahali S. Morgan Kexin Yan Thuy T. Le Ryan A. Johnston Alberto A. Amarilla David A. Muller Christopher L. D. McMillan Naphak Modhiran Daniel Watterson James R. Potter Julian D.J. Sng Mary Lor Devina Paramitha Ariel Isaacs Alexander A. Khromykh Roy A. Hall Andreas Suhrbier Daniel J. Rawle Jody Hobson-Peters |
| author_sort | Mahali S. Morgan |
| collection | DOAJ |
| description | The global coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spawned an ongoing demand for new research reagents and interventions. Herein we describe a panel of monoclonal antibodies raised against SARS-CoV-2. One antibody showed excellent utility for immunohistochemistry, clearly staining infected cells in formalin-fixed and paraffin embedded lungs and brains of mice infected with the original and the omicron variants of SARS-CoV-2. We demonstrate the reactivity to multiple variants of concern using ELISAs and describe the use of the antibodies in indirect immunofluorescence assays, Western blots, and rapid antigen tests. Finally, we illustrate the ability of two antibodies to reduce significantly viral tissue titers in K18-hACE2 transgenic mice infected with the original and an omicron isolate of SARS-CoV-2. |
| first_indexed | 2024-03-09T11:02:16Z |
| format | Article |
| id | doaj.art-82d6e8999d344525a4e59c50bacc8174 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T11:02:16Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-82d6e8999d344525a4e59c50bacc81742023-12-01T01:11:02ZengMDPI AGViruses1999-49152022-12-0115113910.3390/v15010139Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of ConcernMahali S. Morgan0Kexin Yan1Thuy T. Le2Ryan A. Johnston3Alberto A. Amarilla4David A. Muller5Christopher L. D. McMillan6Naphak Modhiran7Daniel Watterson8James R. Potter9Julian D.J. Sng10Mary Lor11Devina Paramitha12Ariel Isaacs13Alexander A. Khromykh14Roy A. Hall15Andreas Suhrbier16Daniel J. Rawle17Jody Hobson-Peters18School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaInflammation Biology, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, AustraliaInflammation Biology, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaInflammation Biology, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaInflammation Biology, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, AustraliaInflammation Biology, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, AustraliaSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, AustraliaThe global coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spawned an ongoing demand for new research reagents and interventions. Herein we describe a panel of monoclonal antibodies raised against SARS-CoV-2. One antibody showed excellent utility for immunohistochemistry, clearly staining infected cells in formalin-fixed and paraffin embedded lungs and brains of mice infected with the original and the omicron variants of SARS-CoV-2. We demonstrate the reactivity to multiple variants of concern using ELISAs and describe the use of the antibodies in indirect immunofluorescence assays, Western blots, and rapid antigen tests. Finally, we illustrate the ability of two antibodies to reduce significantly viral tissue titers in K18-hACE2 transgenic mice infected with the original and an omicron isolate of SARS-CoV-2.https://www.mdpi.com/1999-4915/15/1/139monoclonal antibodySARS-CoV-2immunohistochemistryimmunofluorescenceWestern blottinglateral flow assays |
| spellingShingle | Mahali S. Morgan Kexin Yan Thuy T. Le Ryan A. Johnston Alberto A. Amarilla David A. Muller Christopher L. D. McMillan Naphak Modhiran Daniel Watterson James R. Potter Julian D.J. Sng Mary Lor Devina Paramitha Ariel Isaacs Alexander A. Khromykh Roy A. Hall Andreas Suhrbier Daniel J. Rawle Jody Hobson-Peters Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern Viruses monoclonal antibody SARS-CoV-2 immunohistochemistry immunofluorescence Western blotting lateral flow assays |
| title | Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern |
| title_full | Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern |
| title_fullStr | Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern |
| title_full_unstemmed | Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern |
| title_short | Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern |
| title_sort | monoclonal antibodies specific for sars cov 2 spike protein suitable for multiple applications for current variants of concern |
| topic | monoclonal antibody SARS-CoV-2 immunohistochemistry immunofluorescence Western blotting lateral flow assays |
| url | https://www.mdpi.com/1999-4915/15/1/139 |
| work_keys_str_mv | AT mahalismorgan monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT kexinyan monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT thuytle monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT ryanajohnston monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT albertoaamarilla monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT davidamuller monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT christopherldmcmillan monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT naphakmodhiran monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT danielwatterson monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT jamesrpotter monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT juliandjsng monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT marylor monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT devinaparamitha monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT arielisaacs monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT alexanderakhromykh monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT royahall monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT andreassuhrbier monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT danieljrawle monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern AT jodyhobsonpeters monoclonalantibodiesspecificforsarscov2spikeproteinsuitableformultipleapplicationsforcurrentvariantsofconcern |